Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + anthracycline + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This combination involves **nab-paclitaxel**, a nanoparticle albumin-bound paclitaxel that stabilizes microtubules in cancer cells, preventing their disassembly and thus inhibiting cell division. **Anthracyclines** (e.g., doxorubicin, epirubicin) intercalate DNA strands, inhibiting the synthesis of nucleic acids and inducing apoptosis. **Cyclophosphamide** is an alkylating agent that cross-links DNA strands, leading to cell death. This combination is used in chemotherapy regimens, particularly for breast cancer.
02
Targets
DNAN7-G (DNA guanine-N7 adduct)TOP2A (DNA topoisomerase II)Microtubule
Beyond the preview
Go deeper on nab-paclitaxel + anthracycline + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + anthracycline + cyclophosphamide.